Mechanisms of cancer immunotherapy and pipeline
Focusing on cancers and autoimmune diseases
Fapon Biopharma is dedicated to the R&D of biologics for cancers and auto immune diseases treatment. Our pipeline includes 15 innovative projects covering multiple synergistic mechanisms.
Monoclonal Antibody
FP008：Anti-PD-1 × IL-10M for solid tumors refractory to anti-PD-1/PD-L1 therapy
FP008 is a fusion protein integrating an anti-PD-1 antibody and an IL-10 monomer. It reverses terminally exhausted CD8+ T cells, and exhibits potent anti-tumor effects in transgenic mouse models. Hematological toxicities in cynomolgus monkeys are reduced to mild levels even at high doses, compared to wild-type IL-10-Fc. By reversing the exhausted CD8+ T cells in the tumor microenvironment, this fusion protein provides a promising therapeutic strategy for solid tumors refractory to anti-PD-1/PD-L1 therapy.
Differentiated mechanism
Potent anti-tumor efficacy
Enhancing IL-10‘s activation function when enriched at the target site via the antibody moiety
Demonstrating potent anti-tumor effects in CT26 hPD-1 mouse model
Timeline
To obtain IND approval from the US FDA in January 2025
To obtain IND approval from the China NMPA in May 2025
To start administration in phase 1 clinical trial in 2025
